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Objective: To estimate the incremental cost-effectiveness of the first-line pharmacotherapies (nicotine gum,
patch, spray, inhaler, and bupropion) for smoking cessation across six Western countries—Canada,
France, Spain, Switzerland, the United States, and the United Kingdom.
Design and study population: A Markov-chain cohort model to simulate two cohorts of smokers: (1) a
reference cohort given brief cessation counselling by a general practitioner (GP); (2) a treatment cohort
given counselling plus pharmacotherapy. Effectiveness expressed as odds ratios for quitting associated
with pharmacotherapies. Costs based on the additional physician time required and retail prices of the
medications.
Interventions: Addition of each first-line pharmacotherapy to GP cessation counselling.
Main outcome measures: Cost per life-year saved associated with pharmacotherapies.
Results: The cost per life-year saved for counselling only ranged from US$190 in Spain to $773 in the UK
for men, and from $288 in Spain to $1168 in the UK for women. The incremental cost per life-year saved
for gum ranged from $2230 for men in Spain to $7643 for women in the US; for patch from $1758 for
men in Spain to $5131 for women in the UK; for spray from $1935 for men in Spain to $7969 for women
in the US; for inhaler from $3480 for men in Switzerland to $8700 for women in France; and for
bupropion from $792 for men in Canada to $2922 for women in the US. In sensitivity analysis, changes in
discount rate, treatment effectiveness, and natural quit rate had the strongest influences on cost-
effectiveness.
Conclusions: The cost-effectiveness of the pharmacotherapies varied significantly across the six study
countries, however, in each case, the results would be considered favourable as compared to other
common preventive pharmacotherapies.
T
obacco kills four million people worldwide each year and
is presently one of the leading causes of avoidable
premature death in the developed world.1 The main
principle approaches to slowing the epidemic are prevention
of initiation among young people and cessation among
current tobacco users. Prevention is essential for achieving
medium- and long-term reductions in tobacco-caused mor-
bidity and mortality, while cessation will be the key to
averting millions of deaths among current smokers that are
forecasted for the next 50 years.1 2 Smokers who quit before
the onset of illness will avoid most of the added mortality risk
from smoking, which begins falling within a few years of
cessation.3 4
Pharmacologic smoking cessation therapies—nicotine
delivery through gum, patch, spray, or inhaler, and bupro-
pion, an antidepressant that reduces symptoms of with-
drawal and depression associated with quitting—have been
shown to approximately double a smoker’s odds of quit-
ting successfully when used in adjunction to brief physician
counselling.5–7 It has been emphasised that studying the
extent to which various tobacco dependence drug
therapies are cost-effective requires additional research.7
Previous cost-effectiveness studies have been conducted for
single countries only, limiting the possibility to generalise
their results to other settings where the cost of physicians’
time and/or the pharmacotherapies may differ. Further-
more, previous economic studies of smoking cessation have
used different methods and assumptions for estimating costs
and effectiveness, making comparison between studies
difficult.
To our knowledge, no study has compared cost-effective-
ness of the five first-line pharmacotherapies across several
different countries. In this analysis, we estimated the cost-
effectiveness of the first-line pharmacotherapies for six
Western industrialised countries.
METHODS
We calculated the cost per life-year saved of general
practitioners (GPs) providing their patients each of the five
first-line pharmacotherapies as an adjunct to cessation
counselling for Canada, France, Spain, Switzerland, the
United Kingdom (UK), and the United States (US). We
selected these countries because they provided a broad
perspective that represented Anglo-Saxon, Latin, and
Germanic populations. Table 1 provides a summary of the
most common, relevant characteristics of the health care
system for each study country.8–19 Based on available
evidence, we assumed that the effectiveness of treatment
(that is, counselling and adjuvant pharmacotherapy) and the
associated effects on mortality were the same across all
countries.5 We calculated the costs of the pharmacotherapies
separately for each country based on country-specific data. To
shorten the length of this report, we presented here results
for a 45-year-old man or woman and for the entire cohort
divided into three age categories.
Calculation of effectiveness
We supposed that GPs provided their smoking patients
opportunistic cessation counselling during routine office
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visits and offered pharmacotherapy to those for whom it
was indicated. Clinical guidelines indicate pharmaco-
logic cessation therapy only for smokers who consume
at least 10–15 cigarettes per day.7 A large majority of
daily smokers visiting a GP smoke on average a pack
a day.20–22 Therefore, we included in our simulated
cohorts only patients who smoked, on average, 20 cigarettes
per day.
We used a validated computer-simulated Markov model
to generate two cohorts of identical smokers.23 24 Details can
be found in the appendix entitled Markovmodel.pdf on the
Tobacco Control website— http://www.tobaccocontrol.com.
We characterised the two cohorts according to a set of
base-case assumptions (table 2). The reference cohort
received only cessation counselling from a GP. The second
cohort received the same counselling plus each of the five
pharmacotherapies. We expressed the effectiveness of
adjuvant pharmacotherapy as the additional number of
life-years saved attributable to the offer, use, and follow-up
of each of the five pharmacotherapies. We derived the
effectiveness of counselling and nicotine replacement
therapy (NRT) from two published meta-analyses.5 6 We
based the effectiveness of bupropion on a meta-analysis
performed by the US Department of Health and Human
Services.7 Each of these reference studies based its measure-
ment of cessation status on the point prevalence at one year
of abstinence. We used the reported odds ratios for efficacy
from these studies as our measure of effectiveness for each
form of treatment. We assumed that quit odds ratios were
the same for men and women, the rationale for which has
been presented elsewhere.6 Nicotine spray and nicotine
inhaler were not approved for use in Canada and France,
and Canada and Spain, respectively, so estimates in these
cases could not be included in the analysis.




















Covered on a limited
basis in some
provinces
About 50% of surveyed
patients report having to
initiate conversations with
GPs about smoking cessation
27 23
France10 11 Universal coverage
supplemented by private
insurance; about 50% of care
provided in public facilities,









57% of GPs reported advising
smoking patients to quit; 25%
of smokers’ records indicated
advice having been delivered
39 27
Spain12 13 Universal coverage; direct
public financing, all services
free of charge; provision of
care occurs mostly in public
sector






55% of GPs initiated cessation
counselling; 98% provided
counselling if patient initiated
conversation about cessation or
had symptoms of tobacco-
caused disease (1998 survey)
42 25
Switzerland14 15 Compulsory private health









88% of patients recalled being
asked by GP about their
smoking habits, but only 34%
recalled being counselled to quit
38 27





terms and fees set
by Secretary of State
Covered by public
insurance
Approximately 50% of GPs
advised smoking patients to
quit during most or all
consultations (1999 survey)
29 28
United States18 19 Primarily privately financed
health care and insurance;
public sector finances
significant amount of care
for elderly, some for
disabled and poor









Patient smoking status identified
in 67% of clinic visits, and
cessation counselling provided
in 21% (1995 survey)
28 22
*World Development Indicators, 2002; The World Bank, 2002.
GP, general practitioner; NHS, National Health Service.
Table 2 Variables used in the analysis
Variable
Base case (range for
sensitivity analysis)
Natural cessation rate among all smokers, % 2.5 (1–4)
Proportion of smokers in ‘‘preparation’’
stage, %
25 (10–40)
OR* counselling only 1.73 (1.46–2.03)
OR nicotine gum 1.66 (1.52–1.82)
OR nicotine patch 1.80 (1.61–2.01)
OR nicotine spray 2.35 (1.63–3.38)
OR nicotine inhaler 2.14 (1.44–3.18)
OR bupropion 2.51 (1.5–3.0)
Smokers still under treatment after first
month (%)
50 (40–60)
Smokers still under treatment after second
month (%)
20 (15–25)
Lifetime probability of relapse after one
year of abstinence (%)
35 (10–50)
Time required for counselling (minutes) 10
Additional physician time required (minutes) 90







Discount rate, % 3 (0–5)
*Odds ratio for smoking cessation at one year, as compared to no
intervention.
Incremental odds ratio for cessation at one year, as compared to
counselling only (identical OR for women and men).
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Cessation rates and risk of relapse
We assumed a natural quit rate (that is, cessation without
intervention) of 2.5%. This rate reflects the estimated
probability of quitting smoking over the course of one year
in Switzerland as well as in other Western countries.20 25
Studies have shown that 50–70% of smokers would like to
quit smoking.21 26 Yet, according to the Stages-of-Change
model, a much smaller proportion of these smokers is in the
preparation stage—truly ready to make a serious quit
attempt—and therefore appropriate candidates for pharma-
cotherapy.27 We assumed that 25% of current smokers were
in the preparation stage for quitting.28 The long-term risk of
relapse for former smokers is not well documented. Existing
long-term follow-up data suggest that approximately 30% of
subjects who have been abstinent for one year will relapse
sometime during the following five years.29 30 Relapse after
five years does occur, but the rate is insignificantly low.29 30
From previous studies, we adopted the conservative assump-
tion of a 35% lifetime probability of relapse after one year of
validated abstinence.31 32
Mortality effects of smoking cessation
We based the mortality effects of smoking cessation for
smokers of the six countries on the same data—that is, the
results of the American Cancer Society Prevention Study II
(CPSII)—which compared mortality rates for smokers and
non-smokers up to age 75.29 According to this and other
studies, the excess mortality risk declines significantly after
cessation, and we assume that the mortality rate of former
smokers rejoins that of never smokers approximately 20 years
after quitting.3 4 29 33 Based on the findings of CPSII, we
extrapolated the mortality curves to age 90 and supposed a
phase-in period of 25 years for former smokers’ mortality risk
to return to that of non-smokers.29
Cost of smoking cessation therapies
We assumed a third-party-payer perspective in calculating
medical and non-medical costs of smoking cessation thera-
pies, an approach used in previous cost-effectiveness analyses
of NRT.34 This approach helps facilitate a comparison of our
results with those of existing studies. We based the dosage
and duration of pharmacotherapy on current clinical guide-
lines, which recommend that pharmacologic treatment last
up to three months.7 Physicians commonly recommend that
patients use pharmacotherapy for a minimum of one month,
so we assumed that all smokers in the treatment cohort incur
the costs of at least one month of NRT and bupropion,
respectively. Previous studies suggest that 50% of smokers
who initiate treatment continue for a second month, and
only 30% of those who start continue for a third month.26 35
We estimated pharmacotherapy prices in the study countries
based on pharmacy prices or published price data (view the
appendix on the Tobacco Control website— http://www.tobac-
cocontrol.com). For Canada, we conducted an original survey
of 50 randomly selected retail pharmacies across the country,
weighted by province. For the US, we estimated average
pharmacotherapy prices in January 2003 from two nation-
wide pharmacy chains (CVS, Chapel Hill, North Carolina;
RiteAid, Los Angeles, California). Prices for France, Spain,
Switzerland, and the UK were based on publicly or privately
published price data.36–40 We compared these price data with
those from other sources to verify reliability (for France, Vidal
online 2003: www.vidal.fr; for Spain, Catalogo de
Especialidades Farmaeutica 2002; for Switzerland,
Pharmacia AG Suisse and Galexis 2003 Files; for UK,
MIMS march 2003 par e-mediat AG). We based the costs
associated with physicians’ time on the cost to a third-party-
payer of a general consultation by a GP that does not include
any technical procedures. We collected these data from the
Ontario Medical Association (Ted Broadway, personal com-
munication, December 2002) for Canada, estimates from the
existing literature for France,41 official government data for
Spain, the UK, and the US,42–44 and a private medical data
consulting service for Switzerland.45
Sensitivity analysis
We conducted sensitivity analysis for several of the input
variables (see table 2 for ranges used), which provides an
important illustration of the degree to which cost-effective-
ness changes in response to variations in input values. We
based the sensitivity analysis for treatment efficacy on the
95% confidence interval. The parameters that change by
country were price of inputs to smoking cessation therapy
and physicians fees.
Discounting and currency conversion
To account for the time gap between the costs of the
intervention and the benefits in life-years saved, it is
common practice to calculate the present discounted value
of the earlier-incurred costs and the later-realised benefits,
thereby measuring their value on the same relative scale.23 46
We used a 3% discount rate in our base case analysis, which
adheres to current guidelines for cost-effectiveness analysis.47
However, to present the results in their ‘‘raw’’ form and to
acknowledge other discounting rationales, we included rates
of 0% and 5% in the sensitivity analysis. To enable cross-
country comparisons, we conducted the analysis using US
dollars. We converted monetary data for each country
according to the following 2002/2003 market rates of
exchange for one US dollar: 1.42 Swiss francs, 0.64 British
pounds, 1.01 Euros, and 1.54 Canadian dollars.
RESULTS
The cost per life-year saved for a 45-year-old for counselling
was in ascending order $190 and $288 for men and women in
Spain, $375 and $567 in Switzerland, $389 and $588 in
Canada, $479 and $724 in France, $623 and $941 in the US,
and $773 and $1168 in the UK. This high variation in the
cost-effectiveness of counselling across the six study coun-
tries—the ratios for the UK are four times higher than for
Spain—was due to substantial differences in GPs’ fees. For
example, the hourly rate for a consultation with a GP in
Spain was $33, while in France the rate was 2.5 times higher
at $83 per hour, and in the UK it was four times higher at
$134 per hour.
All cost-effectiveness ratios for pharmacotherapies must be
interpreted in incremental terms, as they reflect the
additional costs and benefits associated with adding phar-
macotherapy to a base of physician counselling. The
incremental cost per life-year saved varied across countries
and pharmacotherapies, but in each case, pharmacotherapy
as an adjunct to counselling yielded a greater number of life-
years saved as compared to average gains from counselling
only. Among the six countries, the incremental cost per life-
year saved for a 45-year-old smoker (tables 3 and 4) ranged
from $2230 for men in Spain to $7643 for women in the US
for gum; $1758 for men in Spain to $5131 for women in the
UK for patch; $1935 for men in Spain to $7969 for women in
the US for spray; $3480 for men in Switzerland to $8700 for
women in France for inhaler; and $792 for men in Canada to
$2922 for women in the US for bupropion. Within
pharmacotherapies, the highest cost-effectiveness ratio ran-
ged from approximately 1.6 higher (inhaler) to almost three
times higher (spray) than the lowest ratio. The most cost-
effective pharmacotherapy for each country was bupropion,
followed by the patch. The ranking of gum, spray, and inhaler
varied across countries, though in many cases, the spray and
inhaler outperformed the gum.
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There was a consistent difference, across all countries and
pharmacotherapies, in cost-effectiveness between men and
women, which proceeds directly from their respective
smoking-caused mortality risk. The mortality curve related
to smoking is steeper for men due to a greater burden of
smoking-caused death and disease, and their burden is
greater than women’s due to greater consumption (that is,
more cigarettes smoked on average) than women.48 Men,
therefore, stand to gain more units of benefit—life-years
saved—from cessation than women, which results in the
intervention being more cost-effective (lower cost-effective-
ness ratios) for men than for women.
Cost-effectiveness ratios differ across all pharmacothera-
pies and countries according to age of patients at the time of
the intervention (tables 5–10). The cost-effectiveness ratio
was lowest among 35–49-year-olds for both sexes. However,
the age class with the highest ratio was the class 20–34 for
the women and the class 50–64 for the men. For example,
among Canadian men, the cost-effectiveness ratio for gum
was $3330 for 20–34-year-olds, $2791 for 35–49-year-olds,
and $3699 for 50–64-year-olds. Among French women, the
cost-effectiveness ratio for the inhaler was $12246 for 20–34-
year-olds, $8924 for 35–49-year-olds, and $9458 for 50–64-
year-olds. For Spanish men, the cost-effectiveness ratio for
the spray was $2285 for 20–34-year-olds, $2208 for 35–49-
year-olds, and $2926 for 50–64-year-olds. Among Swiss men,
the cost-effectiveness ratio for the patch was $3430 for 20–
34-year-olds, $2875 for 35–49-year-olds, and $3810 for 50–
64-year-olds. For men in the UK, the cost-effectiveness ratio
for bupropion was $1762 for 20–34-year-olds, $1477 for 35–
49-year-olds, and $1957 for 50–64-year-olds. And among US
women, the cost-effectiveness ratio for bupropion was $4112
for 20–34-year-olds, $2997 for 35–49-year-olds, and $3176
for 50–64-year-olds. Two dynamics account for this effect of
all pharmacotherapies becoming progressively less cost-
effective as patient age both increased and decreased from
Table 5 Incremental cost per life-year saved by age categories: Canada
Gum Patch Spray Inhaler Bupropion
Men Women Men Women Men Women Men Women Men Women
20–34 3330 5996 2984 5373 N/A N/A N/A N/A 935 1684
35–49 2791 4369 2501 3916 N/A N/A N/A N/A 784 1227
50–64 3699 4631 3315 4150 N/A N/A N/A N/A 1039 1300
N/A, not available.






Ratio*Men Women Men Women Men Women
Spain 2230 3370 1.00 Spain 1758 2657 1.00 Spain 1935 2923 1.00
Canada 2820 4260 1.26 France 2518 3804 1.43 Switzerland 3438 5194 1.78
France 3228 4876 1.45 Canada 2527 3817 1.44 UK 3498 5285 1.81
Switzerland 3612 5457 1.62 Switzerland 2904 4387 1.65 US 5275 7969 2.73
UK 3766 5689 1.69 US 3099 4682 1.76 Canada N/A N/A
US 5059 7643 2.27 UK 3396 5131 1.93 France N/A N/A
*Ratio compared to lowest cost country.





Ratio*Men Women Men Women
Switzerland 3480 5257 1.00 Canada 792 1196 1.00
UK 3716 5614 1.07 Spain 878 1326 1.11
US 5086 7685 1.46 France 1268 1915 1.60
France 5759 8700 1.65 UK 1433 2165 1.81
Canada N/A N/A Switzerland 1492 2254 1.88
Spain N/A N/A US 1934 2922 2.44
*Ratio compared to lowest cost country.
Table 6 Incremental cost per life-year saved by age categories: France
Gum Patch Spray Inhaler Bupropion
Men Women Men Women Men Women Men Women Men Women
20–34 3812 6864 2974 5354 N/A N/A 6802 12246 1498 2696
35–49 3195 5002 2493 3902 N/A N/A 5701 8924 1255 1965
50–64 4234 5301 3303 4135 N/A N/A 7555 9458 1663 2082
N/A, not available.
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the middle-aged group: for the youngest smokers, discount-
ing diminishes the value of the benefits and therefore the
cost-effectiveness of pharmacotherapy; for the older smokers,
the greater probability that they will die before realising all
the benefits of quitting likewise diminishes the cost-effec-
tiveness.
Sensitivity analysis had a significant effect on the cost-
effectiveness of the pharmacotherapies, particularly when
applied to the discount rate, treatment efficacy, and the
natural quit rate. Regarding discount rate, applying a rate of
0% resulted in approximately 45% and 30% lower cost-
effectiveness ratios for men and women, respectively, than
the base case assumption of 3% discount rate. At a discount
rate of 10%, the cost-effectiveness ratios were approximately
66% and 77% higher than at a rate of 3%. This effect was
consistent across all countries and pharmacotherapies. For
treatment efficacy, the effect of sensitivity analysis, based on
the upper and lower bounds of the 95% confidence interval
(CI) for the efficacy odds ratio, was significant across all
countries and pharmacotherapies, as demonstrated for the
patch (fig 1), which showed that the ratios have large
ranges—for example, from 4967 to 5661 for women in
Canada. The effect was particularly pronounced for the spray,
inhaler, and bupropion, raising the cost-effectiveness ratio by
2–3 times at the lower bound for treatment efficacy. This
effect was relatively large because the 95% CIs for these
pharmacotherapies are wide, and the CIs are wide because
there are at present relatively few efficacy studies to include
in meta-analysis for these three pharmacotherapies. Cost-
effectiveness ratios changed between 11–18% when pharma-
cotherapy cost was raised and lowered by 20%, as showed in
the case of patch in fig 2. Cost-effectiveness was also very
sensitive to variations in the natural quit rate. In each case
and across all pharmacotherapies, the cost-effectiveness ratio
was approximately twice as high as the base case at a rate of
1% and was approximately one quarter lower at a rate of 4%.
For example, among women in Spain, the cost-effectiveness
ratio for nicotine gum, which was $3370 according to the
base case assumptions, varied from $7007 to $2512 at natural
quit rates of 1% and 4%, respectively. And for men in Canada,
the cost-effectiveness ratio for bupropion was $792 according
to base case assumptions, and $1661 and $585 at natural quit
rates of 1% and 4%, respectively. Varying the lifetime
relapse rate to 10% and 50% lowered and raised, respectively,
Table 7 Incremental cost per life-year saved by age categories: Spain
Gum Patch Spray Inhaler Bupropion
Men Women Men Women Men Women Men Women Men Women
20–34 2635 4743 2077 3739 2285 4114 N/A N/A 1037 1867
35–49 2208 3456 1741 2725 1915 2998 N/A N/A 869 1361
50–64 2926 3663 2307 2888 2538 3178 N/A N/A 1152 1442
N/A, not available.
Table 8 Incremental cost per life-year saved by age categories: Switzerland
Gum Patch Spray Inhaler Bupropion
Men Women Men Women Men Women Men Women Men Women
20–34 4266 7681 3430 6175 4061 7311 4110 7400 1762 3173
35–49 3576 5597 2875 4500 3404 5328 3445 5392 1477 2312
50–64 4739 5932 3810 4769 4511 5647 4565 5715 1957 2450
Table 9 Incremental cost per life-year saved by age categories: United Kingdom
Gum Patch Spray Inhaler Bupropion
Men Women Men Women Men Women Men Women Men Women
20–34 4448 8008 4011 7221 4132 7439 4389 4389 1692 3047
35–49 3728 5835 3362 5262 3463 5421 3678 5758 1418 2220
50–64 4940 6185 4455 5577 4590 5745 4875 6103 1880 2353
Table 10 Incremental cost per life-year saved by age categories: United States
Gum Patch Spray Inhaler Bupropion
Men Women Men Women Men Women Men Women Men Women
20–34 5976 10758 3661 6591 6230 11217 6008 10816 2284 4112
35–49 5008 7840 3068 4803 5221 8174 5035 7882 1914 2997
50–64 6637 8309 4066 5090 6920 8663 6673 8354 2537 3176
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cost-effectiveness by approximately 25%. Cost-effectiveness
ratios were relatively insensitive to changes in GPs’ fees,
changing by approximately 3–6% when GPs’ fees were raised
and lowered by 15%, as showed for the patch in fig 3.
Variations in the relapse rates during the first and second
months of treatment had only minor effects.
DISCUSSION
The key features of our study are the following: (1) the cost-
effectiveness of counselling highly varied across the six
countries due to substantial differences in GPs’ fees; (2)
pharmacotherapy as an adjunct to counselling yielded a
greater number of life-years saved as compared to average
gains from counselling only; (3) the most cost-effective
pharmacotherapies for each country and both sexes were
bupropion, followed by the patch; (4) the greater burden of
smoking-caused death and disease among men translated
into more unit life-years saved from cessation than women,
which resulted in the intervention being more cost-effective
for men; (5) the cost-effectiveness ratio was highest among
20–34-year-olds and lowest among 35–49-year-olds due to
the mortality curve related to smoking; (6) the sensitivity
analysis highlighted a significant effect of discount rate,
treatment efficacy, and natural quit rate on the cost-
effectiveness ratio.
One of the primary advantages of this multi-country
analysis is its broad perspective, providing current estimates
of cost-effectiveness of pharmacotherapies across several
countries, which is useful in assessing generalisability to
other settings. The variation in cost-effectiveness across the
selected countries is significant, with the difference in some
cases approaching a factor of three—for example, $1935 per
life-year saved for the spray in Spain versus $5275 in the US.
However, when viewed in a broader context, namely in
comparison to other preventive medicine interventions, the
cost-effectiveness ratios for these pharmacotherapies would
be considered favourable for each study country. For
example, a 1998 Canadian study found the cost-effectiveness
of lovastatin for the primary prevention of cardiovascular
disease to range from CAD$11 040 to CAD$52 463 (US$8212
to $39 020 in 2002 US$).49 A 1995 Canadian study found the
cost per life-year saved for hypercholesterolaemia drug
therapies to range from CAD$17 231 to CAD$155 891
(US$18 293 to $199 892 in 2002 US$),50 and a 2000 US
study found the cost per quality-adjusted life-year saved to
range from $54 000 to $1 400 000 ($56 415 to $438 780 in
2002 US$).51 Furthermore, hypertension and hypercholester-
olaemia drug therapies (and their costs) continue throughout
the remainder of the patient’s life, while smoking cessation
treatment (and its costs) lasts only a few months. This
reflects a substantial difference in total lifetime expenditures
per patient between the two types of interventions.
Furthermore, the cost-effectiveness of these pharmacothera-
pies is likely to improve as generic versions—usually
significantly lower in cost than name brand versions—
become more widely available.
A second important value of this multi-country analysis is
that it reveals the specific effects of health care costs on cost-
effectiveness in six unique settings. Both physicians’ fees and
pharmacotherapy prices vary significantly across the selected
countries, by as much as factors of 4.5 and 3.4, respectively.
Overall, pharmacotherapy price has a stronger influence on
the cost-effectiveness ratio than physicians’ time since it
comprises a larger proportion of the total cost of the
intervention. For example, in the case of Spain, the total
cost of GPs’ time for the intervention is $55, while the total
cost of pharmacotherapy ranges from $214 to $432. Even in
the case of the UK, which has the highest GPs’ fees of the six
countries, the total cost of the physician’s time for a three-
month course was estimated to be $223, while pharma-
cotherapy costs range from $253 to $649. In an effort to
maximise the cost-effectiveness of this intervention, it may
be useful for policymakers in countries where the proportion
of physicians’ cost is relatively high—for example, the UK
and the US—to consider training lower-cost health care























Figure 1 Sensitivity of cost-effectiveness of nicotine patch to 95%























Figure 2 Sensitivity of cost-effectiveness of nicotine patch to 20%























Figure 3 Sensitivity of cost-effectiveness of nicotine patch to 15%
change in general practitioners’ fees (US$).
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The sensitivity analysis stresses the role of assessing not
only the usual variables in such analysis (that is, discount
rate and treatment efficacy), but also baseline or natural
probability of having the clinical outcome (that is, quitting
rate in our case), since the cost-effectiveness ratio of
pharmacotherapies increases by a factor of three when
natural quit rate goes from 4% to 1%.
Presently, the time spent by physicians counselling
patients to quit smoking, prescribing, and following up
pharmacotherapy is reimbursed by public or private insur-
ance in each country as time spent in patient consultation
(table 1). In each case, however, there is evidence that 50% or
more of GPs do not recommend quitting and pharmacother-
apy to their patients for whom it is indicated. On the
contrary, the cost of the pharmacotherapies is in most
common circumstances not reimbursable and is therefore
paid out-of-pocket by the patient in each of the six countries.
The keys to increasing the use and coverage of pharma-
cotherapies will be twofold: encouraging GPs to system-
atically recommend quitting and using pharmacotherapies to
the smoking patients, and making pharmacotherapy as
accessible as possible to appropriate smokers.
It is also useful to compare our results with existing cost-
effectiveness analyses of NRT, bearing in mind that metho-
dological differences play a significant role in the variation
across results. One US study found the incremental cost per
life-year saved associated with nicotine gum to range from
$4167 to $9473 ($6840 to $15 549 in 2002 US$).34 Two other
US studies found the incremental cost per life-year saved
associated with the nicotine patch to be $1796 to $4391
($2013 to $4922 in 2002 US$) and $4390 to $10 943 ($5034
to $12 547 in 2002 US$), respectively.31 32 Both these studies
of the patch assumed a treatment course of two months
(versus three months in our study), which alone itself would
lower cost-effectiveness ratios by one-third as compared to
ours. A 2002 UK study estimated that the incremental cost
per life-year saved for NRT was £2399 ($3598 in 2002 US$)
and for bupropion was £1969 ($2953 in 2002 US$).52 Another
2002 UK study calculated the incremental cost per life-year
saved associated with bupropion to be between US$920 to
US$2150.53
Our study has some limitations. First, due to a lack of
available evidence, we were unable to account for variations
in treatment effectiveness across individuals or countries.
Some potential influences could be age, cigarette consump-
tion, socioeconomic status, and race, or social value given to
cessation as related possibly to a country’s tobacco control
policies, such as level of cigarette tax or restrictions on
advertising and smoking in public places. Second, we used
life-years saved as the measure of benefit and not disability-
adjusted life years (DALYs), which also account for time
spent living with tobacco-caused disease. Applying DALYs is
likely to improve cost-effectiveness of pharmacotherapies.
We opted instead to take the more conservative approach
because there exists some debate regarding the derivation of
the measure, in particular the disagreements among
researchers with either the assumptions behind DALYs or
the methods of calculation.54 55 Third, instead of using
exchange rates to convert national currencies to US dollars,
we might have used purchasing power parity, a parameter
also appropriate for international comparison. However,
using one current device, such as US dollars, to enable cross
country comparisons let us put our results in an important
perspective—that is, the comparison with cost-effectiveness
ratios of other medical and preventive interventions, as
mentioned above. Furthermore, our option ensures interna-
tional Tobacco Control readers are able to compare data for
their own country to other data they may know in other
health care fields from the medical literature. Overall the data
would have been on the same magnitude, albeit the
differences between countries would have been a little bit
smaller. Finally, a single, standardised data source for all
study countries was not available, so there was some
variability in the level or method by which data were
collected (for example, pharmacy survey versus government
data versus private consulting service data for treatment
prices). We did, however, compare pharmacotherapy price
data to those collected by another, independent source and
confirmed that they were acceptably similar.
Conclusion
The cost-effectiveness of the first line pharmacotherapies for
smoking cessation varied significantly across Canada, France,
Spain, Switzerland, the United Kingdom, and the United
States. In each case, bupropion and secondly the patch were
the most cost-effective treatments. In each country, pharma-
cotherapies for smoking cessation would be considered
favourable in terms of cost-effectiveness as compared to
several other common preventive drug treatments.
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What this paper adds
Pharmacologic smoking cessation therapies have been
shown to be cost-effective only in single settings.
Our Markov-chain cohort model simulating two cohorts of
smokers shows that the incremental cost-effectiveness of the
first-line pharmacotherapies (nicotine gum, patch, spray,
inhaler, and bupropion) varied significantly across Canada,
France, Spain, Switzerland, the United States, and the United
Kingdom, with the difference in some cases approaching a
factor of three. However, in each case, the results would be
considered favourable as compared to other common
preventive pharmacotherapies. Sensitivity analysis shows
that changes in discount rate, treatment effectiveness, and
natural quit rate have the strongest influences on cost-
effectiveness.
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